Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Clinical trial NCT05425745 · COMPLETED

Trial details

NCT number: NCT05425745
Sponsor: NewAmsterdam Pharma
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Dyslipidemias High Cholesterol Hypercholesterolemia Familial Hypercholesterolemia Lipid Metabolism Disorder Metabolic Disease Lipid Metabolism, Inborn Errors Genetic Disease, Inborn Hyperlipoproteinemias

Start date: 2022-07-25
Primary completion: 2024-05-28
Enrollment: 354

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.